Abstracts tagged "meta-analysis"

Abstract Number: 875 • 2014 ACR/ARHP Annual Meeting
Treatment-Related Outcomes in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: A Pooled Analysis of 12 Randomized Controlled Trials
Rennie L. Rhee¹, Nicole B. Gabler², Amy Praestgaard², Peter A. Merkel³ and Steven M. Kawut⁴, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴Pulmonary and Critical Care, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Recent studies have shown that therapies for pulmonary arterial hypertension (PAH) improve exercise capacity, but subgroup analyses suggest that these therapies may be less…
Abstract Number: 747 • 2014 ACR/ARHP Annual Meeting
Systemic Sclerosis Patients with Antitopoisomerase Antibodies Showed Significant Association with CCR6 Polymorphisms
Javier Martin¹, Eguzkine Ochoa², Jose Ezequiel Martin¹, Shervin Assassi³, Lorenzo Beretta⁴, Patricia Carreira⁵, Carmen Pilar Simeon⁶, Eugénie Koumakis⁷, Philippe Dieude⁸, Yannick Allanore⁹, Francisco J. García-Hernández¹⁰, Gerard Espinosa¹¹, Ivan Castellvi Barranco¹², Luis Trapiella¹³, Luis Rodriguez Rodriguez¹⁴, Miguel A González-Gay¹⁵, María-Victoria Egurbide¹⁶, Luis Saez¹⁷, José Luis Callejas¹⁸, JA Vargas-Hitos¹⁹, Nicolas Hunzelmann²⁰, Gabriela Riemekasten²¹, Torsten Witte²², Jörg HW Distler²³, Alexander Kreuter²⁴, Claudio Lunardi²⁵, Alessandro Santaniello²⁶, Filemon K. Tan³, Frank C. Arnett³, Paul Shiels²⁷, Ariane L. Herrick²⁸, Jane Worthington²⁹, Madelon C. Vonk³⁰, Bobby P.C. Koeleman³¹, T.R.D.J. Radstake³² and Maureen Mayes³³, ¹Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, ²Immunology, Instituto de Parasitología y Biomedicina Lopez Neyra (IPBLN-CSIC), Granada, Spain, ³Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁴Via Francesco Sforza 28, Ospedale Maggiore Policlinico, Milano, Italy, ⁵Hospital Universitario 12 de Octubre, Department of Rheumatology, Madrid, Spain, ⁶Servicio de Medicina Interna, Hospital Valle de Hebron, Barcelona, Spain, ⁷Rheumatology A department, Cochin Hospital, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ⁸Rhumatologie, Hopital Bichat Claude Bernard, Paris, France, ⁹Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France, ¹⁰Internal Medicine, Hospital Virgen del Rocío, Sevilla, Spain, ¹¹Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Spain, ¹²Hosp. De Sta. Creu i S. Pau, Vilafranca del Pened, Spain, ¹³Department of Internal Medicine,, Hospital Universitario Central de Asturias, Asturias, Spain, ¹⁴Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ¹⁵Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ¹⁶Autoimmune Disease Research Unit, Service of Internal Medicine,, Hospital de Cruces, UPV/EHU, Barakaldo, Spain, Barakaldo, Spain, ¹⁷Unidad de Enfermedades Autoinmunes, Servicio de Medicina Interna, Hospital Miguel Servet, Zaragoza, Spain, ¹⁸Internal Medicine, Hospital Clínico San Cecilio, Granada, Spain, ¹⁹Internal Medicine, Hospital Universitario Virgen de las Nieves, Granada, Spain, ²⁰Department of Dermatology, University of Cologne, Cologne, Germany, ²¹Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, ²²Clinic for Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ²³Department of Internal Medicine, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²⁴Department of Dermatology, Venereology, and Allergologie, HELIOS St. Elisabeth Hospital, Oberhausen, Germany, ²⁵Department of Medicine, Università degli Studi di Verona, Verona, Italy, ²⁶Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ²⁷University of Glasgow, Glasgow, United Kingdom, ²⁸Musculoskeletal Research Group, School of Translational Medicine, Manchester Academic Health Science Centre, Salford Royal Hospital, University of Manchester., Salford, United Kingdom, ²⁹Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, ³⁰Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³¹Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, ³²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³³Internal Medicine/Rheumatology, University of TX Health Science Center -Houston, Houston, TX
Background/Purpose: Systemic sclerosis (SSc), also known as scleroderma, is an inflammatory autoimmune disease characterized by fibrosis of the skin and internal organs, vascular damage and…
Abstract Number: 745 • 2013 ACR/ARHP Annual Meeting
Rate Of Infection and Development Of Malignancy In Patients With ANCA-Associated Vasculitis Treated With Rituximab: A Meta-Analysis From Randomized Trials
Carolina Mejia-Otero¹, Carlos J. Lozada² and Luis Arias-Urdaneta³, ¹Internal Medicine, Mount Sinai Medical Center, Miami, FL, ²Dept of Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ³Rheumatology, Mount Sinai Medical Center, Miami Beach, FL
Background/Purpose: Over the past 40 years failures to achieve remission in a proportion of patients and the potential development of significant adverse effects have been…
Abstract Number: 498 • 2013 ACR/ARHP Annual Meeting
A Systematic Review and Meta-Analysis Comparing Low- Versus High-Dose Rituximab For Rheumatoid Arthritis
Markus Bredemeier, Fernando K. de Oliveira and Claúdia M. Rocha, Rheumatology, Hospital Nossa Senhora da Conceição - Grupo Hospitalar Conceição, Porto Alegre, Brazil
Background/Purpose: The approved dose of rituximab (RTX) for rheumatoid arthritis (RA) is 2x1000 mg infusions given 2 weeks apart. There is contradictory evidence regarding the…
Abstract Number: 460 • 2013 ACR/ARHP Annual Meeting
Comparative Efficacy Of Novel Disease-Modifying Antirheumatic Drugs As Monotherapy and In Combination With Methotrexate In Rheumatoid Arthritis Patients With An Inadequate Response To Traditional Disease-Modifying Antirheumatic Drugs: A Network Meta-Analysis
Felicity Buckley¹, Axel Finckh², Thomas W.J. Huizinga³, Fred Dejonckheere⁴ and Jeroen P. Jansen¹, ¹MAPI Consultancy, Boston, MA, ²Department of Medical Specialities, University of Geneva, Geneva, Switzerland, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland
Background/Purpose: To compare ACR responses of novel DMARDs as monotherapy or in combination with methotrexate (MTX), including subcutaneous (SC) abatacept and SC tocilizumab (TCZ), in…
Abstract Number: 472 • 2013 ACR/ARHP Annual Meeting
Clinical Efficacy Rate Of The Non-Specific Effect (the placebo effect) In The Tumour Necrosis Factor Inhibitors For Rheumatoid Arthritis Treatment After Methotrexate Failure: Meta-Analysis
Julie Azaïs¹, Thomas Barnetche², Pascale Vergne-Salle³, Christine Bonnet⁴, Carine Dufauret-Lombard⁵, Richard Treves⁶ and Philippe Bertin⁷, ¹Rheumatology department, CHU Dupuytren Limoges, Limoges, France, ²Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France, ³Rheumatology, CHU Dupuytren Limoges, limoges, France, ⁴department of Rheumatology, CHU Dupuytren Limoges, Limoges, France, ⁵Rheumatology, CHU Dupuytren Limoges, Limoges, France, ⁶Department of Rheumatology, CHU Dupuytren Limoges, Limoges, France, ⁷Service De Rhumatologie, CHU Dupuytren Limoges, Limoges, France
Background/Purpose: Therapeutics generate non-specific effects (the placebo effect), and specific ones, like the 5 tumor necrosis factor (TNF) inhibitors used in the treatment of Rheumatoid…
Abstract Number: 283 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Biologic Treatments In Juvenile Idiopathic Arthritis With a Polyarticular Course: An Indirect Comparison
Laura Sawyer¹, Alex Diamantopoulos², Hermine Brunner³, Fabrizio De Benedetti⁴, Nicolino Ruperto⁵, Fred Dejonckheere⁶ and Caroline Keane⁷, ¹Symmetron Limited, London, United Kingdom, ²Symmetron Limited, Herts, United Kingdom, ³PRCSG, Cincinnati, OH, ⁴Division of Rheumatology, Department of Pediatric Medicine, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁵PRINTO, Genoa, Italy, ⁶F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁷Roche, Welwyn Garden City, United Kingdom
Background/Purpose: To date there are no head-to-head trials comparing the efficacy of biologic treatments for polyarticular-course JIA (pcJIA). The purpose of this study was to…
Abstract Number: 2337 • 2013 ACR/ARHP Annual Meeting
Serious Adverse Events Associated With Using Biological Agents To Treat Rheumatic Diseases: Network Meta-Analysis From a National Guideline Panel
Simon Tarp¹, Ulrik Tarp², Lis S. Andersen³, Tove Lorenzen⁴, Hanne M. Lindegaard⁵, Michael Stoltenberg⁶, Hanne S. Jensen⁷, Birgitte Brock⁸, Camilla M. Mikkelsen⁹, Dorte V. Jensen¹⁰, Karsten Asmussen⁷, Troels Herlin¹¹ and Robin Christensen¹, ¹Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ²Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Department of Rheumatology, Copenhagen University Hospital, Gentofte, Denmark, ⁴Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, ⁵Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁶Department of Rheumatology, Copenhagen University Hospital, Køge, Denmark, ⁷Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ⁸Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark, ⁹The Capital Region of Denmark Hospital Pharmacy, Medicine Information Centre, Copenhagen NV, Denmark, ¹⁰The Danish Rheumatologic Database (DANBIO), Center of Rheumatology and Spine Diseases VRR, Copenhagen University Hospital, Glostrup, Denmark, ¹¹Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Clinical guidelines are needed to help clinicians provide optimal medical treatment and advise patients about the potential hazards associated with certain drugs. Our objective…
Abstract Number: 1564 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Influenza Vaccination Is Strongly Decreased In Systemic Lupus Erythematosus: A Meta-Analysis Of Literature Data
Laurent Arnaud¹, Alexis Mathian², Hervé Devilliers³, Du Boutin-LE Thi Huong⁴, Ahlem Chaib⁴, Fleur Cohen-Aubart⁴, Julien Haroche¹, Miguel Hié⁴, Makoto Miyara⁴ and Zahir Amoura⁴, ¹Internal Medicine, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ²Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ³Internal medicine and systemic disease unit, Dijon University Hospital, Dijon, France, ⁴Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France
Background/Purpose: Several studies suggest that the efficacy of influenza vaccination may be decreased in systemic lupus erythematosus (SLE). We performed a meta-analysis to assess systematically…
Abstract Number: 1471 • 2013 ACR/ARHP Annual Meeting
Tofacitinib For Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Maria A. Lopez-Olivo¹, Maria E. Suarez-Almazor² and Mahesh Bavineni³, ¹General Internal Medicine, University of Texas. M.D Anderson Cancer Center, Houston, TX, ²The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Internal Medicine, Louisiana State University Lafayette, Lafayette, LA
Background/Purpose: Tofacitinib was developed as a small molecule inhibitor of the Janus kinase (JAK) pathways that are central to the maintenance of the inflammatory state…
Abstract Number: 2408 • 2012 ACR/ARHP Annual Meeting
Effects of Ground and Joint Reaction Force Exercise On Bone Mineral Density in Postmenopausal Women: A Meta-Analysis of Randomized Controlled Trials
George A. Kelley¹, Kristi S. Kelley¹ and Wendy M. Kohrt², ¹Biostatistics, West Virginia University, Morgantown, WV, ²Geriatric Medicine, University of Colorado @ Denver, Aurora, CO
Background/Purpose: Previous randomized controlled trials have led to conflicting findings regarding the effects of ground and/or joint reaction force exercise on femoral neck (FN) and…
Abstract Number: 2171 • 2012 ACR/ARHP Annual Meeting
Comparative Efficacy of Biologics As Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with an Inadequate Response to Conventional Dmards: A Network Meta-Analysis
Felicity Buckley¹, Axel Finckh², Thomas W. Huizinga³, Fred Dejonckheere⁴ and Jeroen P. Jansen¹, ¹MAPI Consultancy, Boston, MA, ²Rhumatology, University Hospital of Geneva, Geneva, Switzerland, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland
Background/Purpose: A number of meta-analyses compare the efficacy of biologics for rheumatoid arthritis (RA). However, systematic reviews comparing the efficacy of biologics as monotherapy versus…
Abstract Number: 1543 • 2012 ACR/ARHP Annual Meeting
Rituximab for ANCA-Associated Vasculitis: A Meta-Analysis of Randomized Trials
Carolina Mejia¹ and Carlos J. Lozada², ¹Internal Medicine, Mount Sinai Medical Center, Miami, FL, ²Dept of Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL
Background/Purpose: Over the past 40 years, cyclophosphamide/glucocorticoids combination therapy has been the standard regimen for remission induction in ANCA-associated vasculitis.. Although a major advance in…
Abstract Number: 1052 • 2012 ACR/ARHP Annual Meeting
Systematic Review of the Association Between Magnetic Resonance Imaging and Radiographic Detection of Erosions in Rheumatoid Arthritis
Ruben Tavares¹, Stephen R. Tytus², Karen A. Beattie³, Maggie Larche⁴, Naveen Parasu⁵, Colin E. Webber⁶, Lawrence E. Hart⁷ and Jonathan D. Adachi⁸, ¹McMaster University, Hamilton, ON, Canada, ²Northern Ontario School of Medicine, Sudbury, ON, Qatar, ³Medicine, McMaster University, Hamilton, ON, Canada, ⁴Rheumatology, McMaster University, Hamilton, ON, Canada, ⁵Radiology, Hamilton Health Sciences, Hamilton, ON, Canada, ⁶Department of Nuclear Medicine, Hamilton Health Sciences, Hamilton, ON, Canada, ⁷Medicine (Rheumatology), St. Joseph's Health Care, Hamilton, ON, Canada, ⁸St Joseph's Healthcare Hamilton, Hamilton, ON, Canada
Background/Purpose: In rheumatoid arthritis (RA), disparities between erosive bone lesion detection on magnetic resonance imaging (MRI) and X-ray require reconciliation. It is hypothesized that early…
Abstract Number: 2685 • 2012 ACR/ARHP Annual Meeting
Overall and Cause Specific Mortality in Patients with Systemic Lupus Erythematosus. A Meta-Analysis of Observational Studies
Marko Yurkovich¹, Kateryna Vostretsova² and J. Antonio Avina-Zubieta³, ¹Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada/University of British Columbia, Richmond, BC, Canada
Background/Purpose: Systemic lupus erythematosus (SLE), is a chronic autoimmune condition. It has the potential to affect any organ system and can be associated with severe…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].